System and method for evaluating physiological parameter data

Information

  • Patent Grant
  • 8275553
  • Patent Number
    8,275,553
  • Date Filed
    Wednesday, February 18, 2009
    15 years ago
  • Date Issued
    Tuesday, September 25, 2012
    11 years ago
Abstract
Embodiments disclosed herein may include systems and methods for evaluating physiological parameter data. Embodiments of methods may include monitoring a patient to produce a signal comprising a sequence of numerical values for a physiological parameter over a time period, calculating an index from the signal, comparing the index to a reported index, and if the index is greater than the reported index, setting the reported index to the value of the index. Embodiments of methods may include calculating a modulation of the signal, comparing the modulation to a previous value of the modulation to identify a trend in the modulation and if the trend corresponds to an undesirable condition, using a first function to increase the reported index. Embodiments of methods may include providing an indication of a physiological status based on the reported index.
Description
BACKGROUND

Embodiments of the present disclosure may relate to a system and method for evaluating physiological parameter data. In embodiments, a medical device may be capable of calculating an airway instability index from pulse oximetry measurements and generating a smoothed index representing airway instability.


This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present disclosure, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with information to facilitate a better understanding of the various aspects of the present disclosure. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.


Obstructive sleep apnea is a condition in which a patient's breathing is temporarily interrupted when sleeping. The condition is believed to be associated with increased fat deposits in the neck, which commonly occur as a patient ages. These increased fat deposits may lead to a narrowing of the airway. When muscle tone diminishes during sleep, the narrowed airway can collapse during inhalation, effectively stopping and/or severely limiting air movement. At this point, the choking patient typically attempts to inhale more deeply, which generally results in further collapsing the airway. With no air movement, the oxygen level in the patient's bloodstream falls, finally reaching a point where the patient is aroused out of sleep. Upon arousal, the muscle tone increases, the airway opens and air flow to the lungs is precipitously restored. The patient hyperventilates, which quickly restores the blood oxygen levels to normal levels. The period of arousal is brief, so the patient is often unaware that the event took place. The patient returns to sleeping and the cycle often repeats.


Over time, this repeating cycle of low oxygen levels in the bloodstream can damage the heart and lead to other serious medical complications. Obstructive sleep apnea is believed to be one of the most common disorders in the United States and an important cause of heart attack and stroke. However, unlike other common medical disorders, such as diabetes, no simple diagnostic test has been developed to determine if a patient has sleep apnea. Tests do exist that can be used to diagnose sleep apnea, but the tests typically involve an overnight sleep study, which can be costly and inconvenient. The need for a simple, low-cost diagnostic test has led medical personnel to try less expensive techniques, such as pulse oximetry, to diagnose the presence of obstructive sleep apnea.


SUMMARY

Certain aspects of embodiments of this disclosure are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the disclosure might take and that these aspects are not intended to limit the scope of the disclosure. Indeed, the disclosure may encompass a variety of aspects that may not be set forth below.


Embodiments may include a method of evaluating physiological parameter data. The method may include monitoring a patient to produce a signal including a sequence of numerical values for a physiological parameter over a time period and calculating an index from the signal. The index may be compared to a reported index and if the index is greater than the reported index, the reported index may be set to the value of the index. A modulation of the signal may be calculated and compared to a previous value of the modulation to identify a trend in the modulation. If the trend corresponds to an undesirable condition, a first function may be used to increase the reported index. The reported index may be used to provide an indication of a physiological status.


Embodiments may include a medical device including a sensor, a microprocessor, a memory, and a display. The sensor may be configured to produce a signal including a sequence of numerical values for a physiological parameter over a time period and the microprocessor may be configured to process the signal. The memory may be configured for storing programs and the contents of the memory may include machine readable instructions configured to direct the microprocessor to obtain the signal from the sensor and calculate an index from the signal. The instructions may, if executed, direct the microprocessor to compare the index to a reported index and if the index is greater than the reported index, set the reported index to the value of the index. The instructions may also direct the microprocessor to calculate a modulation of the signal and compare the modulation to a previous value of the modulation to identify a trend in the modulation. If the trend corresponds to an undesirable condition, the machine readable instructions may direct the microprocessor to increase the reported index using a first function. Finally, the memory may include instructions to direct the microprocessor to provide an indication of a physiological status based on the reported index.


Embodiments may include a tangible, machine readable medium that may include code which, if executed, may cause a microprocessor to obtain a signal made up of a sequence of numerical values for a physiological parameter over a time period and calculate an index from the signal. The tangible, machine readable medium may additionally include code that compares the index to a reported index and if the index is greater than the reported index, set the reported index to the value of the index, and code to calculate a modulation of the signal and compare the modulation to a previous value of the modulation to identify a trend in the modulation. If the trend corresponds to an undesirable condition, the code may increase the reported index using a first function. Finally, the tangible machine-readable medium may include code to provide an indication of a physiological status based on the reported index.





BRIEF DESCRIPTION OF THE DRAWINGS

Advantages of the disclosure may become apparent upon reading the following detailed description and upon reference to the drawings in which:



FIG. 1 is a block diagram of a system for the collection of a physiological parameter in accordance with embodiments;



FIG. 2 is a block diagram of an electronic device or pattern detection feature in accordance with present embodiments;



FIG. 3 is an exemplary graph including an SpO2 trend that contains a ventilatory instability SpO2 pattern and a trend of the resulting SPDi in accordance with embodiments;



FIG. 4 is a process flow diagram showing a method for minimization of noise in the calculation of an airway instability index in accordance with embodiments;



FIG. 5 is a graphical representation of SpO2 data which may be useful to explain the operation of embodiments with respect to short term decreases in an index;



FIG. 6 is a graphical representation of SpO2 data which may be useful to explain the operation of embodiments with respect to significant increases in an index;



FIG. 7 is a graphical representation of SpO2 data which may be useful to explain the operation of embodiments with respect to lowered noise response; and



FIG. 8 is a graphical representation of SpO2 data which may be useful to explain the operation of an embodiment of the present invention with respect to significant decreases in SpO2.





DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS

Embodiments will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.


Medical devices may be used to obtain signals representing physiological parameters from patients. However, these signals, which may be sequences of numerical values over time, may have too much information or noise to be effectively used in the diagnosis or treatment of certain medical conditions. Accordingly, the signals may be processed to generate a secondary series of numerical values over time, termed an index, which may provide a more useful representation of the status of the medical condition. In some applications, the index itself may be too responsive to noise or other factors to be easily analyzed. Embodiments may include methods that may be useful for processing an index calculated from a signal to generate a reported index having a decreased response to noise and other clinically insignificant events.


Thus, methods may assist in identifying problematic physiological conditions, while reducing the incidence of nuisance alarms. For example, in an embodiment, a method may increase the effectiveness of the use of oxygen saturation levels obtained from pulse oximetry in the diagnosis and treatment of sleep apnea. However, one of ordinary skill in the art will recognize that the method described below is not limited to pulse oximetry and may be implemented on other systems to calculate indices reflective of other physiological conditions. Examples of such indices may include indices reflective of heart rate variability, brain activity, glucose levels, and other measurements.



FIG. 1 is a block diagram of a medical device 10, which may be used in embodiments. The medical device 10 may have a sensor 12 configured for the collection of a signal representing a physiological parameter. The sensor 12 may be an optical sensor used with a pulse oximeter for the measurement of oxygen saturation in the bloodstream. Furthermore, the sensor 12 may include electrodes for measuring electrical signals from the heart or brain of a patient. The signal from the sensor 12 may be conditioned by an interface 14 prior to being utilized by a microprocessor 16.


In an embodiment, the microprocessor 16 may be connected to random access memory (RAM) 18 and/or read-only memory (ROM) 20. The RAM 18 may be used to store the signals from the sensor 12 and the results of calculations that the microprocessor 16 performs. The ROM 20 may contain code, e.g., machine readable instructions, to direct the microprocessor 16 in collecting and processing the signal. In an embodiment, the microprocessor 16 may be connected to an input device 22 which may be used for local entry of control and calculation parameters for the medical device 10. A display unit 24 may be connected to the microprocessor 16 to display the results the microprocessor 16 has generated from the signal representing the physiological parameter.


In an embodiment, the microprocessor 16 may also be connected to a network interface 26 for the transfer of data from the microprocessor 16 to devices connected to a local area network 28. In an embodiment, the transferred data may include signal data, indices representing the status of physiological conditions, alarm signals, other data, and/or any combination thereof. The transferred data may also consist of control signals from the devices on the local area network 28, for example, to instruct the medical device 10 to send signal data, or other information, to a device on the local area network 28.


In embodiments, the medical device 10 may be used to calculate a reported index with the data collected from the sensor 12, using the method discussed below. The reported index may be output to the display unit 24 or sent to a network device on the local area network 28. The processing may take place in real time, or may be run after the data collection is completed for later determination of an index representing a physiological parameter.


In embodiments, a network device located on the local area network 28 may be used to calculate a reported index with the data collected from the sensor 12, using the method discussed below. The network device may request that the signal be sent from the medical device 10 through the network interface 26. As for the embodiment discussed above, the network device may be used to either determine an index representing a physiological condition in real time or to process a previously collected signal.


In an embodiment, the value of the index representing a physiological condition may be used to trigger one or more alarms, alerting practitioners to clinically important conditions. These alarms may appear on devices on the local area network 28, for example, a patient monitoring screen in an ICU. Alternatively, the alarms may appear on the display unit 24 of the medical device 10. Further, it may be advantageous to activate alarms in both locations using the results from either a local calculation on the medical device 10 or from a remote calculation on a network device connected to the local area network 28.


Embodiments may include a method for the calculation of a smoothed, reported index indicating the status of a medical condition. The method may be used to calculate a reported index indicative of airway instability from blood oxygen saturation data (SpO2). An airway instability index may be used to sound alarms during apnea events or to automatically control treatment systems. The method may utilize information that may occur during each sleep apnea event, called a desaturation pattern or pattern, in which the blood oxygen level falls slowly as oxygen stores in the body are used up, and then sharply recovers as the patient is aroused and hyperventilates. The recurring apnea events may occur in groups of at least two successive patterns, called clusters. In an embodiment, the severity of the apnea may be determined from the number of patterns in each cluster, the time between each pattern, the slope of the drop in the blood oxygen level during a pattern and the slope of the recovery of the blood oxygen level as the patterns ends, and other indications, and/or combinations thereof, among others.


In embodiments, the method may use a number of indices, which may be calculated from the clusters and patterns, to indicate the presence or severity of airway instability, which may be directly related to obstructive sleep apnea, and/or other apneaic events. Embodiments of these indices may include a saturation to ventilation index, an oxygen repletion index, and/or an apnea recovery index, and/or combinations thereof, among others.


In an embodiment, an aggregate index may also be calculated based on the number of breaths, the relative magnitude of the breaths, the slope of the initial 50% of the descending limbs of the desaturations within the cluster and the duration of the clusters, and/or combinations thereof. Embodiments may include an index representing airway instability and may be calculated in a similar manner to those discussed in U.S. Pat. No. 6,760,608 (hereinafter the '608 patent), incorporated by reference as if fully set forth herein. Although the airway instability index may provide a numerical measure of the airway instability and, thus, the presence of apnea, it may have too high of a response to noise or other small changes to be desirable.


In accordance with some embodiments, the airway instability index may include a saturation pattern detection index (SPDi). The SPDi may be defined as a scoring metric associated with the identification of a saturation trend pattern generated in accordance with present embodiment and may correlate to ventilatory instability in a population of sleep lab patients. Specifically, the SPDi may be based on identified clusters of qualified reciprocations in pulse oximetry data. The reciprocations may be identified and qualified using methods and devices as set forth in U.S. Provisional Application No. 61/110,299 filed Oct. 31, 2008, which is incorporated herein by reference in its entirety.


In order to calculate the SPDi, the patterns (i.e., clusters of qualified reciprocations) in SpO2 trend data must first be detected. Accordingly, present embodiments may include code stored on a tangible, computer-readable medium (e.g., a memory) and/or hardware (in the medical device 10 and/or a computer, for instance) capable of detecting the presence of certain patterns in a series of physiologic data. For example, FIG. 2 is a block diagram of an electronic device or pattern detection feature in accordance with present embodiments. The electronic device is generally indicated by the reference number 100 and it may be part of the medical device 10 and/or a separate computer. The electronic device 100 (e.g., an SpO2 monitor and/or memory device) may comprise various subsystems represented as functional blocks in FIG. 2. The various functional blocks shown in FIG. 2 may comprise hardware elements (e.g., circuitry), software elements (e.g., computer code stored on a hard drive or other tangible computer-readable medium) or a combination of both hardware and software elements. For example, each functional block may represent software code and/or hardware components that are configured to perform portions of an algorithm in accordance with present embodiments.


Specifically, in the illustrated embodiment, the electronic device 100 includes a reciprocation detection (RD) feature 102, a reciprocation qualification (RQ) feature 104, a cluster determination (CD) feature 106, a saturation pattern detection index (SPDi) calculation feature 108, and a user notification (UN) feature 110. Each of these components and the coordination of their functions will be summarized and discussed in further detail below. Additional description of these features may be found in U.S. Provisional Application No. 61/110,299 filed Oct. 31, 2008, which is incorporated herein by reference in its entirety.


The RD feature 102 may be capable of performing an algorithm for detecting reciprocations in a data trend. Specifically, the algorithm of the RD feature 102 may perform a statistical method to find potential reciprocation peaks and nadirs in a trend of SpO2 data. A nadir may be defined as a minimum SpO2 value in a reciprocation. The peaks may include a rise peak (e.g., a maximum SpO2 value in a reciprocation that occurs after the nadir) and/or a fall peak (e.g., a maximum SpO2 value in a reciprocation that occurs before the nadir).


In one embodiment, a window size for calculations related to identifying peaks and nadirs may be set based on historical values (e.g., average duration of a set number of previous reciprocations). For example, in one embodiment, a window size may be set to the average duration of all qualified reciprocations in a certain time period (e.g., the last 6 minutes) divided by 2. In another embodiment, a dynamic window method may be utilized wherein the window size may be initially set to a certain amount of time (e.g., 12 seconds) and then increased as the length of qualified reciprocations increases. This may be done in anticipation of larger reciprocations because reciprocations that occur next to each other tend to be of similar shape and size. If the window remained at the initial time setting (e.g., 12 seconds), it could potentially be too short for larger reciprocations and may prematurely detect peaks and nadirs. The following equation or calculation is representative of a window size determination, wherein the output of the filter is inclusively limited to 12-36 seconds, and the equation is executed each time a new reciprocation is qualified:


If no qualified reciprocations in the last 6 minutes:


Window Size=12 (initial value)


else:

RecipDur=½*current qualified recip duration+½*previous RecipDur


Window Size=bound(RecipDur,12,36).


With regard to SpO2 signals that are essentially flat, the dynamic window method may fail to find the three points (i.e., a fall peak, a rise peak, and a nadir) utilized to identify a potential reciprocation. Therefore, the RD feature 102 may limit the amount of time that the dynamic window method can search for a potential reciprocation. For example, if no reciprocations are found in 240 seconds plus the current dynamic window size, the algorithm of the RD feature 102 may timeout and begin to look for potential reciprocations at the current SpO2 trend point and later. The net effect of this may be that the RD feature 102 detects potential reciprocations less than 240 seconds long.


Once potential peaks and nadirs are found using the RD feature 102, the RQ feature 104 may pass the potential reciprocations through one or more qualification stages to determine if a related event is caused by ventilatory instability. A first qualification stage may include checking reciprocation metrics against a set of limits (e.g., predetermined hard limits). A second qualification stage may include a linear qualification function. In accordance with present embodiments, a potential reciprocation may be required to pass through both stages in order to be qualified. Details regarding these qualification stages may be found in U.S. Provisional Application No. 61/110,299 filed Oct. 31, 2008, which is incorporated herein by reference in its entirety.


As an example, in a first qualification stage, which may include a limit-based qualification, four metrics may be calculated for each potential reciprocation and compared to a set of limits. Any reciprocation with a metric that falls outside of these limits may be disqualified. The limits may be based on empirical data. For example, in some embodiments, the limits may be selected by calculating the metrics for potential reciprocations from sleep lab data where ventilatory instability is known to be present, and then comparing the results to metrics from motion and breathe-down studies. The limits may then be refined to filter out true positives.


A second qualification stage of the RQ feature 104 may utilize a object reciprocation qualification feature. Specifically, the second qualification stage may utilize a linear qualification function based on ease of implementation, efficiency, and ease of optimization. The equation may be determined by performing a least squares analysis. For example, such an analysis may be performed with MATLAB®. The inputs to the equation may include the set of metrics disclosed in U.S. Provisional Application No. 61/110,299 filed Oct. 31, 2008. The output may be optimized to a maximum value for patterns where ventilatory instability is known to be present. The equation may be optimized to output smaller values (e.g., 0) for other data sets where potential false positive reciprocations are abundant.


The CD feature 106 may be capable of performing an algorithm that maintains an internal reciprocation counter that keeps track of a number of qualified reciprocations that are currently present. When the reciprocation counter is greater than or equal to a certain value, such as 5, the clustering state may be set to “active” and the algorithm may begin calculating and reporting the SPDi. When clustering is not active (e.g., reciprocation count<5) the algorithm may not calculate the SPDi. Once clustering is active, it may remain active until the time between two qualified reciprocations exceeds a certain time value, such as 120 seconds.


When the clustering state is active, the SPDi calculation feature 108 may calculate an unfiltered SPDi for each new qualified reciprocation. The following formula is an example of a formula that may be used by the SPDi calculation feature 108:

Unfiltered SPDi=a*Magnitude+b*PeakDelta+c*NadirDelta;


wherein a=1.4, b=2.0, c=0.2;


wherein Magnitude=average magnitude of all reciprocations in the last 6 minutes;


wherein PeakDelta=average of the three highest qualified reciprocation rise peaks in the last 6 minutes minus the average of the three lowest qualified reciprocation rise peaks in the last 6 minutes; and


wherein NadirDelta=average of the three highest qualified reciprocation nadirs in the last 6 minutes minus the average of the three lowest qualified reciprocation nadirs in the last 6 minutes.


The above formula may be utilized to quantify the severity of a ventilatory instability pattern. The constants and metrics used may be based on input from clinical team members. It should be noted that the PeakDelta parameter may be assigned the largest weighting constant since the most severe patterns generally have peak reciprocation values that do not recover to the same baseline.


The unfiltered SPDi may be updated whenever clustering is active and a new qualified reciprocation is detected. Non-zero SPDi values may be latched for a period of time (e.g., 6 minutes). The unfiltered SPDi may then be low pass filtered to produce the final output SPDi value. The following infinite impulse response (IIR) filter with a response time of approximately 40 seconds is an example of what may be used:

SPDi=Unfiltered SPDi/a+Previous Filtered SPDi*(a−1)/a;


wherein a=40.



FIG. 3 is an exemplary graph 160 including an SpO2 trend 162 that contains a ventilatory instability SpO2 pattern and a trend of the resulting SPDi 164. In the illustrated example, it should be noted that the SPDi is sensitive to the decreasing peaks (incomplete recoveries) starting at approximately t=6000.


The UN feature 110 may be capable of determining if a user notification function should be employed to notify a user (e.g., via a graphical or audible indicator) of the presence of a detected patterns such as ventilatory instability. The determination of the UN feature 110 may be based on a user configurable tolerance setting and the current value of the SPDi. For example, the user may have four choices for the sensitivity or tolerance setting: Off, Low, Medium, and High. When the sensitivity or tolerance setting is set to Off, an alarm based on detection of a saturation pattern may never be reported to the user. The other three tolerance settings (i.e., Low, Medium, and High) may each map to an SPDi threshold value. For example, Low may map to an SPDi threshold of 6, Medium may map to an SPDi threshold of 15, and High may map to an SPDi threshold of 24. The thresholds may be based on input from users. When the SPDi is at or above the threshold for a given tolerance setting, the user may be notified that ventilatory instability is present.



FIG. 4 is a process flow diagram showing an embodiment of a method 230 capable of the minimization of noise in the calculation of an airway instability index. The method 230 may begin with the collection of a new sample of the percent saturation of oxygen in the bloodstream, or SpO2, as shown in block 232. Over time, these samples provide a signal representing the SpO2 level. After the collection of each new SpO2 sample, the signal may be analyzed to determine if a new, or qualified, pattern has been detected, as shown in block 234. In an embodiment, this determination may be performed by any number of different techniques. One of ordinary skill in the art will appreciate that other methods may be used for the determination of the presence of qualified patterns and/or other patterns.


In an embodiment, if a qualified pattern is detected, the starting time of the qualified pattern may be reported and a new airway instability index may be calculated, as shown in block 236. The airway instability index may be calculated, for example, by using the method set forth above, the method disclosed in the '608 patent, or the method disclosed in U.S. Provisional Application No. 61/110,299 filed Oct. 31, 2008. One of ordinary skill in the art will appreciate that other methods may be used for calculation of an effective airway instability index.


In an embodiment, as shown in block 238, the new value for the airway instability index may be compared to the last value of the airway instability index, and if it is less than or equal to that value, the method 230 may proceed with the acts starting at block 240, as discussed below. The new value for the airway instability index may then be compared to the current value of the reported index, as shown in block 242, and if it is less then or equal to the current value of the reported index, the method 230 may proceed with the acts starting at block 240.


In an embodiment, if the new value for the airway instability index is greater than the current value of the reported index, the reported index may be set to the new value of the airway instability index, as shown in block 244. A decay coefficient may be then calculated for use in the remaining acts, as shown in block 246. In an embodiment, the decay coefficient may be calculated by the formula of the general form shown in equation 1:

R=T2/(Airway Instability Index),   (equation 1)

where T is the desired decay period. In an embodiment, T is 180 seconds. Those skilled in the art will recognize that other values may be used for T, and in fact, T may be tuned to give optimum values needed for the particular application and index selected.


In an embodiment, if no new pattern is detected, and/or upon completion of the acts discussed above, in block 240, a value may be calculated for the percent modulation of the SpO2 trend over the duration of the current qualified pattern. In an embodiment, a fixed or variable length sliding window could also be for the percent modulation and mean calculations. In an embodiment, this calculation may be performed using the formula of the general form shown in equation 2:

Percent Modulation=(SpO2max−SpO2min)/SpO2mean.   (equation 2)

As shown in block 248, the calculated value for the percent modulation may be compared to the previous value of the percent modulation. If the percent modulation has decreased or is unchanged from the last value, the reported index may be decreased, as shown in block 250. In an embodiment, this decrease in the reported index may be performed by using the parabolic decay function of the general form shown in equation 3:

New Reported Index=Previous Preported Index−(2N/R),   (equation 3)

where N is the duration of the current qualified pattern in seconds, calculated from the starting time recorded in block 236, and R is the decay coefficient calculated in equation 1. If the value calculated for the reported index is less than zero, the reported index may be set to zero. One of ordinary skill in the art will recognize that other functions may be selected for decreasing the value of the new unfiltered index. Such functions may include exponential decay functions, quadratic functions, and/or other functions appropriate for the application and index selected. The choice of the function may depend on, for example, the noise of the unfiltered index, the sensitivity desired, and/or the desired response to sudden changes in the index. In an embodiment, an exponential decay function may be desired if a faster response to changes is desirable.


In an embodiment, if the value for percent modulation has increased, the instability index may be increased, as shown in block 252. In an embodiment, this calculation may be performed using a parabolic growth function of the general form shown in equation 4:

New Reported Index=Previous Reported Index+(2N/R),   (equation 4)

where N is the duration of the current qualified pattern in seconds, calculated from the starting time recorded in block 236, and R is the decay coefficient calculated in block 246. If the value calculated for the reported index is greater then a maximum value for the airway instability index selected, then the reported index may be set to the maximum value. One skilled in the art will recognize that other functions may be selected for increasing the value of the reported index. Such functions may include exponential growth functions, quadratic functions, or other functions appropriate for the application and index selected. The selection of an appropriate function will depend on the responsiveness desired, as the function will control how fast the reported index increases or decreases.


In an embodiment, the reported index may be subjected to a filtering step prior to reporting the value of the index, as shown in block 254. In an embodiment, this filtering step may be performed by an infinite impulse response (IIR) filter, of the general form shown in equation 5:

Reported Index=New Reported Index/W+Previous Reported Index*((W−1)/W),   (equation 5)

where W is the IIR filter weight. In an embodiment, a weight of four is used. One skilled in the art will recognize that other weights, or even other functions, may be selected for filtering the value of the new unfiltered index. Alternate weights may be selected to optimize performance of the filter for the index selected. Examples of other filtering functions that may be used include functions such as mean filters, median filters, Gaussian smoothing functions, Savitzky-Golay filters, and/or other functions appropriate for the application and index selected. The choice of the filtering function depends on factors such as the sensitivity desired and the amount of tolerable fluctuation, or noise, in the index, among others.



FIGS. 5-8 are graphs showing the output from embodiments of methods such as, but not limited to, method 230 discussed above. In each of these charts, the left hand vertical axis 256 represents the value of the oxygen saturation, or SpO2, in the blood of a patient. The horizontal axis 258 represents the time, in seconds, of a data collection sequence. Accordingly, the SpO2 signal 260 from a pulse oximeter output may be plotted against these axes 256, 258 to show the change in the blood oxygen level of a patient over time.


The SpO2 signal 260 may be used to calculate an airway instability index 262, which may be useful in determining if a patient is having an episode of obstructive sleep apnea and/or other event. The airway instability index 262 may also be used by the method 230 discussed with respect to FIG. 4 to create a reported index 264, which may have less noise than the airway instability index 262 and, thus, may be more valuable to a practitioner. In the charts of FIGS. 5-8, both the airway instability index 262 and the reported index 264 are plotted against the right hand axis 266, which represents a relative measure for the two indices 262, 264. One of ordinary skill in the art will recognize that similar results will be obtained from the method 230 as applied to indices measuring other physiological parameters.


The line 268, drawn across the chart at the 85% level for SpO2, may indicate a level that may generally be considered important by practitioners. This level may be used as a setpoint in embodiments.



FIG. 5 is a graph showing SpO2 data which may be useful to demonstrate the stability of an embodiment when very short term decreases occur in an index. In an embodiment, the relatively high variability and rapid changes that may occur in an airway instability index 262 may be exemplified by the sudden drop at around 19870 seconds followed by a sudden rise at around 19970 seconds, as indicated by reference number 270. The magnitude and short time span of these changes may be dismissed by a practitioner as happening over too short of a time scale to be a physiologically significant indicator of patient condition or of recovery from a previous pattern.


In contrast, the reported index 264, generated by the method 230 discussed with respect to FIG. 4 shows a relatively small continuing decrease throughout those time periods. Because the reported index 264 is higher than the rapidly changing airway instability index 262, the clinician may already be on alert that issues may be present. In another example, with regard to FIG. 4, the precipitous drop at around 20070 seconds, indicated by reference numeral 272, may be interpreted as an oversensitivity of the airway instability index 262, rather than a meaningful indicator of patient condition or recovery. In contrast to this, the reported index 264 from a method shows a gradual decrease during this period.


A practitioner may be more likely to be concerned with significant shifts upward in the airway instability index 262, than with the downward shifts discussed above. As shown in blocks 242 and 244 of the flowchart in FIG. 4, when the airway instability index 262 is greater than the reported index 264, the reported index 264 may be set to the value of the airway instability index 262. The results of this are illustrated in the chart of FIG. 6, which is useful to demonstrate the response of an embodiment to sudden increases in an index. Precipitous rises in the airway instability index 262, as seen around 6160 and 6250 seconds (indicated by reference numeral 274), may result in corresponding increases in the reported index 264, ensuring that the clinician is warned when significant increases occur.


In an embodiment, the stability of the method 230 to fast changes in the airway instability index 262, e.g., noise, is also demonstrated in FIG. 6. For example, the precipitous downward shifts in the airway instability index 262 at around 6340 and 6400 seconds followed by upward shifts at around 6430 and 6470 seconds (indicated by reference numeral 276) do not cause a significant change in the reported index 264, as the reported index 264 is already at a higher value than the airway instability index 262.


In an embodiment, the decreased response to noise provided by the method 230 is further illustrated by the chart in FIG. 7. In FIG. 7, the airway instability index 262 is falling over time, but shows numerous deviations up and down that may tend to obscure this trend. In contrast, the reported index 264 shows a relatively smooth decrease over the same time period, highlighting the trend.



FIG. 8 is chart of SpO2 data which may be useful to demonstrate the operation of an embodiment as the patient enters a clinically significant period. In FIG. 8, both the stability and responsiveness of the current method are demonstrated. While the airway instability index 262 shows a number of decreases and increases, only a few of the changes are likely to be significant to a practitioner. The reported index 264 immediately follows any upward shift in the airway instability index 262 that is greater then the current value of the reported index 264 while ignoring sudden decreases that are already below the current value of the reported index 264. Thus, the reported index 264 may only show fast changes at clinically significant points.


While the present disclosure described above may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the present disclosure is not intended to be limited to calculating an airway instability index. Indeed, the present disclosure may not only be applied to airway instability indices, but may also be utilized for the reporting of other physiological parameters needing a high response to significant events with low noise. The present disclosure is intended to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present disclosure as defined by the following appended claims.

Claims
  • 1. A method of evaluating physiological parameter data, comprising: monitoring a patient to produce a signal comprising a sequence of numerical values for a physiological parameter over a time period;calculating an index based at least in part upon the signal;comparing the calculated index to a reported index, and if the calculated index is greater than the reported index, setting the reported index to the value of the calculated index;calculating a modulation of the signal, wherein the modulation comprises the difference between a maximum value of the signal and a minimum value of the signal divided by a mean value of the signal over a period of time;comparing the modulation to a previous value of the modulation of the signal to identify a trend in the modulation, and if the trend corresponds to an undesirable condition, using a first function capable of increasing the reported index; andproviding an indication of a physiological status based at least in part upon the reported index.
  • 2. The method of claim 1, wherein the index comprises an airway instability index.
  • 3. The method of claim 1, wherein the period of time comprises a period of time over which a qualified pattern is occurring.
  • 4. A method of evaluating physiological parameter data, comprising: monitoring a patient to produce a signal comprising a sequence of numerical values for a physiological parameter over a time period;calculating an index based at least in part upon the signal;comparing the calculated index to a reported index, and if the calculated index is greater than the reported index, setting the reported index to the value of the calculated index;calculating a modulation of the signal;comparing the modulation to a previous value of the modulation of the signal to identify a trend in the modulation, and if the trend corresponds to an undesirable condition, using a first function capable of increasing the reported index, wherein the first function comprises a parabolic growth function, and/or an exponential growth function; andproviding an indication of a physiological status based at least in part upon the reported index.
  • 5. The method of claim 4, comprising applying a second function capable of decreasing the reported index, if the trend does not correspond to an unfavorable condition.
  • 6. A method of evaluating physiological parameter data, comprising: monitoring a patient to produce a signal comprising a sequence of numerical values for a physiological parameter over a time period;calculating an index based at least in part upon the signal;comparing the calculated index to a reported index, and if the calculated index is greater than the reported index, setting the reported index to the value of the calculated index;calculating a modulation of the signal,comparing the modulation to a previous value of the modulation of the signal to identify a trend in the modulation, and if the trend corresponds to an undesirable condition, using a first function capable of increasing the reported index;applying a second function capable of decreasing the reported index, if the trend does not correspond to an unfavorable condition;filtering the reported index by a third function, wherein the third function comprises an infinite impulse response filter; andproviding an indication of a physiological status based at least in part upon the reported index.
  • 7. A medical device, comprising: a microprocessor configured to process a signal associated with at least one physiological parameter of a patient; anda memory configured to store machine readable instructions which, if executed, are capable of causing the microprocessor to: calculate an index from the signal;compare the calculated index to a reported index, and if the calculated index is greater than the reported index, set the reported index to the value of the calculated index;calculate a modulation of the numerical signal, wherein the modulation comprises the difference between a maximum value of the numerical signal and a minimum value of the numerical signal divided by a mean value of the numerical signal over a period of time;compare the modulation to a previous value of the modulation to identify a trend in the modulation, and if the trend corresponds to an undesirable condition, increase the reported index using a first function; andprovide an indication of a physiological status based on the reported index.
  • 8. The medical device of claim 7, wherein the contents of the memory comprises machine readable instructions which, if executed, are capable of causing the microprocessor to apply a second function to decrease the reported index, if the trend does not correspond to an unfavorable condition.
  • 9. The medical device of claim 8, wherein the machine readable instructions, if executed, are capable of causing the microprocessor to filter the reported index by a third function.
  • 10. The medical device of claim 7, comprising a network interface unit capable of sending information comprising the numerical signal, and/or the reported index, to a device located on a local area network.
  • 11. The medical device of claim 7, wherein the index comprises an airway instability index.
  • 12. A medical device, comprising: a microprocessor configured to process a signal associated with at least one physiological parameter of a patient; anda memory configured to store machine readable instructions which, if executed, are capable of causing the microprocessor to: calculate an index from the signal;compare the calculated index to a reported index, and if the calculated index is greater than the reported index, set the reported index to the value of the calculated index;calculate a modulation of the numerical signal;compare the modulation to a previous value of the modulation to identify a trend in the modulation, and if the trend corresponds to an undesirable condition, increase the reported index using a first function, wherein the first function comprises a parabolic growth function, and/or an exponential growth function; andprovide an indication of a physiological status based on the reported index.
  • 13. A medical device, comprising: a microprocessor configured to process a signal associated with at least one physiological parameter of a patient; anda memory configured to store machine readable instructions which, if executed, are capable of causing the microprocessor to: calculate an index from the signal;compare the calculated index to a reported index, and if the calculated index is greater than the reported index, set the reported index to the value of the calculated index;calculate a modulation of the numerical signal;compare the modulation to a previous value of the modulation to identify a trend in the modulation, and if the trend corresponds to an undesirable condition, increase the reported index using a first function;apply a second function to decrease the reported index, if the trend does not correspond to an unfavorable condition;filter the reported index by a third function, wherein the third function comprises an infinite impulse response filter; andprovide an indication of a physiological status based on the reported index.
  • 14. A method of evaluating physiological parameter data, comprising: monitoring a patient to produce a signal comprising a sequence of numerical values for a physiological parameter over a time period;detecting potential reciprocations by detecting potential reciprocation peaks and nadirs in the sequence of numerical values;determining whether the potential reciprocations are qualified by comparing metrics of the potential reciprocations with a set of limits and performing a linear qualification function;tracking a number of qualified reciprocations identified within a window of time and calculating an index when the number of qualified reciprocations identified within the window of time reaches or surpasses a limit;comparing the calculated index to a reported index, and if the calculated index is greater than the reported index, setting the reported index to the value of the calculated index; andproviding an indication of a physiological status based at least in part upon the reported index.
  • 15. The method of claim 14, comprising: calculating a modulation of the signal; andcomparing the modulation to a previous value of the modulation to identify a trend in the modulation and if the trend corresponds to an undesirable condition, using a first function capable of increasing the reported index.
  • 16. The method of claim 14, comprising calculating the index based at least in part upon an average magnitude of all qualified reciprocations within a time period relative to the current time, an average of a fixed number of the highest reciprocation peaks of qualified reciprocations within the time period, and/or an average of a fixed number of the highest reciprocation nadirs of qualified reciprocations within the time period, and/or combinations thereof.
  • 17. The method of claim 14, wherein the window of time may be defined based on historical values.
RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No 61/066,181, filed Feb. 19, 2008, and is incorporated herein by reference in its entirety.

US Referenced Citations (391)
Number Name Date Kind
3638640 Shaw Feb 1972 A
4106503 Rosenthal et al. Aug 1978 A
4365636 Barker Dec 1982 A
4523279 Sperinde Jun 1985 A
4630614 Atlas Dec 1986 A
4651746 Wall Mar 1987 A
4714341 Hamaguri et al. Dec 1987 A
4738266 Thatcher Apr 1988 A
4757824 Chaumet Jul 1988 A
4765340 Sakai et al. Aug 1988 A
4802485 Bowers et al. Feb 1989 A
4805623 Jöbsis Feb 1989 A
4807631 Hersh et al. Feb 1989 A
4869253 Craig Sep 1989 A
4911167 Corenman et al. Mar 1990 A
4913150 Cheung et al. Apr 1990 A
4936679 Mersch Jun 1990 A
4938218 Goodman et al. Jul 1990 A
4971062 Hasebe et al. Nov 1990 A
4972331 Chance Nov 1990 A
4974591 Awazu et al. Dec 1990 A
5028787 Rosenthal et al. Jul 1991 A
5065749 Hasebe et al. Nov 1991 A
5084327 Stengel Jan 1992 A
5111817 Clark et al. May 1992 A
5119815 Chance Jun 1992 A
5122974 Chance Jun 1992 A
5123420 Paret Jun 1992 A
5134995 Gruenke et al. Aug 1992 A
5167230 Chance Dec 1992 A
5190038 Polson et al. Mar 1993 A
5199424 Sullivan Apr 1993 A
5206807 Hatke Apr 1993 A
5218962 Mannheimer et al. Jun 1993 A
5233983 Markowitz Aug 1993 A
5246003 DeLonzor Sep 1993 A
5247931 Norwood Sep 1993 A
5263244 Centa et al. Nov 1993 A
5275159 Griebel Jan 1994 A
5279295 Martens et al. Jan 1994 A
5297548 Pologe Mar 1994 A
5303699 Bonassa et al. Apr 1994 A
5318597 Hauck et al. Jun 1994 A
5329931 Clauson et al. Jul 1994 A
5335654 Rapoport Aug 1994 A
5353788 Miles Oct 1994 A
5355880 Thomas et al. Oct 1994 A
5368026 Swedlow et al. Nov 1994 A
5372136 Steuer et al. Dec 1994 A
5385143 Aoyagi Jan 1995 A
5385144 Yamanishi et al. Jan 1995 A
5390670 Centa et al. Feb 1995 A
5398682 Lynn Mar 1995 A
5413099 Schmidt et al. May 1995 A
5469845 DeLonzor et al. Nov 1995 A
5482036 Diab et al. Jan 1996 A
5483646 Uchikoga Jan 1996 A
5483969 Testerman Jan 1996 A
5485851 Erickson Jan 1996 A
5490502 Rapoport et al. Feb 1996 A
5535739 Rapoport et al. Jul 1996 A
5540733 Testerman et al. Jul 1996 A
5549106 Gruenke et al. Aug 1996 A
5551419 Froehlich et al. Sep 1996 A
5553614 Chance Sep 1996 A
5564417 Chance Oct 1996 A
5575285 Takanashi et al. Nov 1996 A
5605151 Lynn Feb 1997 A
5611337 Bukta Mar 1997 A
5630413 Thomas et al. May 1997 A
5632270 O'Mahony et al. May 1997 A
5645053 Remmers et al. Jul 1997 A
5645054 Cotner et al. Jul 1997 A
5645059 Fein et al. Jul 1997 A
5645060 Yorkey Jul 1997 A
5680857 Pelikan et al. Oct 1997 A
5682878 Ogden Nov 1997 A
5692503 Keunstner Dec 1997 A
5704345 Berthon/Jones Jan 1998 A
5730124 Yamauchi Mar 1998 A
5730144 Katz et al. Mar 1998 A
5740795 Brydon Apr 1998 A
5743250 Gonda et al. Apr 1998 A
5749900 Schroeppel et al. May 1998 A
5751911 Goldman May 1998 A
5758644 Diab et al. Jun 1998 A
5765563 Vander Schaaf Jun 1998 A
5769084 Katz et al. Jun 1998 A
5779631 Chance Jul 1998 A
5782240 Raviv et al. Jul 1998 A
5782757 Diab et al. Jul 1998 A
5786592 Hök Jul 1998 A
5794614 Gruenke et al. Aug 1998 A
5794615 Estes Aug 1998 A
5803065 Zdrojkowski et al. Sep 1998 A
5803066 Rapoport et al. Sep 1998 A
5823187 Estes et al. Oct 1998 A
5827179 Lichter et al. Oct 1998 A
5830135 Bosque et al. Nov 1998 A
5830136 DeLonzor et al. Nov 1998 A
5830139 Abreu Nov 1998 A
5831598 Kauffert et al. Nov 1998 A
5842981 Larsen et al. Dec 1998 A
5845636 Gruenke et al. Dec 1998 A
5853364 Baker et al. Dec 1998 A
5865173 Froehlich Feb 1999 A
5865736 Baker, Jr. et al. Feb 1999 A
5871442 Madarasz et al. Feb 1999 A
5873821 Chance et al. Feb 1999 A
5891022 Pologe Apr 1999 A
5891023 Lynn Apr 1999 A
5902250 Verrier et al. May 1999 A
5920263 Huttenhoff et al. Jul 1999 A
5957885 Bollish Sep 1999 A
5995855 Kiani et al. Nov 1999 A
5995856 Mannheimer et al. Nov 1999 A
5995859 Takahashi Nov 1999 A
6006379 Hensley Dec 1999 A
6011986 Diab et al. Jan 2000 A
6015388 Sackner et al. Jan 2000 A
6064898 Aldrich May 2000 A
6081742 Amano et al. Jun 2000 A
6083156 Lisiecki Jul 2000 A
6088607 Diab et al. Jul 2000 A
6105575 Estes et al. Aug 2000 A
6120441 Griebel Sep 2000 A
6120460 Abreu Sep 2000 A
6134460 Chance Oct 2000 A
6138675 Berthon/Jones Oct 2000 A
6144877 DePetrillo Nov 2000 A
6148814 Clemmer et al. Nov 2000 A
6150951 Olejniczak Nov 2000 A
6154667 Miura et al. Nov 2000 A
6163715 Larsen et al. Dec 2000 A
6181958 Steuer et al. Jan 2001 B1
6181959 Schöllermann et al. Jan 2001 B1
6190324 Kieval et al. Feb 2001 B1
6215403 Chan et al. Apr 2001 B1
6216032 Griffin et al. Apr 2001 B1
6223064 Lynn et al. Apr 2001 B1
6230035 Aoyagi et al. May 2001 B1
6266546 Steuer et al. Jul 2001 B1
6285895 Ristolainen et al. Sep 2001 B1
6286508 Remmers et al. Sep 2001 B1
6299581 Rapoport et al. Oct 2001 B1
6305374 Zdrojkowski et al. Oct 2001 B1
6312393 Abreu Nov 2001 B1
6322515 Goor et al. Nov 2001 B1
6342039 Lynn et al. Jan 2002 B1
6345619 Finn Feb 2002 B1
6353750 Kimura et al. Mar 2002 B1
6360114 Diab et al. Mar 2002 B1
6367474 Berthon/Jones et al. Apr 2002 B1
6371113 Tobia et al. Apr 2002 B1
6375623 Gavriely Apr 2002 B1
6397091 Diab et al. May 2002 B2
6397092 Norris et al. May 2002 B1
6401713 Hill et al. Jun 2002 B1
6415236 Kobayashi et al. Jul 2002 B2
6419671 Lemberg Jul 2002 B1
6425861 Haberland et al. Jul 2002 B1
6438399 Kurth Aug 2002 B1
6449501 Reuss Sep 2002 B1
6461305 Schnall Oct 2002 B1
6463326 Hartley et al. Oct 2002 B1
6466809 Riley Oct 2002 B1
6487439 Skladnev et al. Nov 2002 B1
6488634 Rapoport et al. Dec 2002 B1
6501974 Huiku Dec 2002 B2
6501975 Diab et al. Dec 2002 B2
6502572 Berthon/Jones et al. Jan 2003 B1
6519486 Edgar, Jr. et al. Feb 2003 B1
6526301 Larsen et al. Feb 2003 B2
6529752 Krausman et al. Mar 2003 B2
6532960 Yurko Mar 2003 B1
6539940 Zdrojkowski et al. Apr 2003 B2
6542764 Al/Ali et al. Apr 2003 B1
6544193 Abreu Apr 2003 B2
6546267 Sugiura et al. Apr 2003 B1
6549795 Chance Apr 2003 B1
6572557 Tchou et al. Jun 2003 B2
6580086 Schulz et al. Jun 2003 B1
6591122 Schmitt Jul 2003 B2
6594513 Jobsis et al. Jul 2003 B1
6606509 Schmitt Aug 2003 B2
6606511 Ali et al. Aug 2003 B1
6609016 Lynn Aug 2003 B1
6609517 Estes et al. Aug 2003 B1
6615064 Aldrich Sep 2003 B1
6618042 Powell Sep 2003 B1
6622095 Kobayashi et al. Sep 2003 B2
6622726 Du Sep 2003 B1
6637434 Noble Oct 2003 B2
6640806 Yurko Nov 2003 B2
6641542 Cho et al. Nov 2003 B2
6654621 Palatnik et al. Nov 2003 B2
6654624 Diab et al. Nov 2003 B2
6658276 Kianl et al. Dec 2003 B2
6658277 Wasserman Dec 2003 B2
6661161 Lanzo et al. Dec 2003 B1
6662030 Khalil et al. Dec 2003 B2
6668183 Hicks et al. Dec 2003 B2
6671526 Aoyagi et al. Dec 2003 B1
6671528 Steuer et al. Dec 2003 B2
6675797 Berthon/Jones Jan 2004 B1
6678543 Diab et al. Jan 2004 B2
6684090 Ali et al. Jan 2004 B2
6690958 Walker et al. Feb 2004 B1
6691705 Dittman et al. Feb 2004 B2
6697658 Al-Ali Feb 2004 B2
6708048 Chance Mar 2004 B1
6711424 Fine et al. Mar 2004 B1
6711425 Reuss Mar 2004 B1
6714245 Ono Mar 2004 B1
6719705 Mills Apr 2004 B2
6731274 Powell May 2004 B2
6745764 Hickle Jun 2004 B2
6748252 Lynn Jun 2004 B2
6760608 Lynn Jul 2004 B2
6761167 Nadjafizadeh et al. Jul 2004 B1
6785568 Chance Aug 2004 B2
6793654 Lemberg Sep 2004 B2
6801797 Mannheimer et al. Oct 2004 B2
6801798 Geddes et al. Oct 2004 B2
6801799 Mendelson Oct 2004 B2
6804656 Rosenfeld et al. Oct 2004 B1
6807965 Hickle Oct 2004 B1
6814074 Nadjafizadeh et al. Nov 2004 B1
6817361 Berthon/Jones et al. Nov 2004 B2
6822564 Al/Ali Nov 2004 B2
6829496 Nagai et al. Dec 2004 B2
6832200 Greeven et al. Dec 2004 B2
6839581 El-Solh et al. Jan 2005 B1
6850053 Daalmans et al. Feb 2005 B2
6863652 Huang et al. Mar 2005 B2
6873865 Steuer et al. Mar 2005 B2
6889153 Dietiker May 2005 B2
6896660 Jelliffe et al. May 2005 B2
6898451 Wuori May 2005 B2
6932084 Estes et al. Aug 2005 B2
6939307 Dunlop Sep 2005 B1
6947780 Scharf Sep 2005 B2
6948497 Zdrojkowski et al. Sep 2005 B2
6949081 Chance Sep 2005 B1
6961598 Diab Nov 2005 B2
6983178 Fine et al. Jan 2006 B2
6988498 Berthon-Jones Jan 2006 B2
6993371 Kiani et al. Jan 2006 B2
6996427 Ali et al. Feb 2006 B2
7006676 Zeylikovich et al. Feb 2006 B1
7024235 Melker et al. Apr 2006 B2
7027849 Al-Ali Apr 2006 B2
7030749 Al-Ali Apr 2006 B2
7031857 Tarassenko et al. Apr 2006 B2
7035697 Brown Apr 2006 B1
7047056 Hannula et al. May 2006 B2
7081095 Lynn et al. Jul 2006 B2
7090648 Sackner et al. Aug 2006 B2
7123950 Mannheimer Oct 2006 B2
7127278 Melker et al. Oct 2006 B2
7153263 Carter et al. Dec 2006 B2
7162306 Caby et al. Jan 2007 B2
7209775 Bae et al. Apr 2007 B2
7225013 Geva et al. May 2007 B2
7236811 Schmitt Jun 2007 B2
7246620 Conroy, Jr. Jul 2007 B2
7247154 Hickle Jul 2007 B2
7263395 Chan et al. Aug 2007 B2
7272426 Schmid Sep 2007 B2
7297119 Westbrook et al. Nov 2007 B2
7309314 Grant et al. Dec 2007 B2
7338447 Phillips Mar 2008 B2
7349727 Obata et al. Mar 2008 B2
7366569 Belalcazar Apr 2008 B2
7373193 Al-Ali et al. May 2008 B2
7383105 Conroy, Jr. Jun 2008 B2
7398115 Lynn Jul 2008 B2
7407486 Huiku et al. Aug 2008 B2
7438687 Lewicke Oct 2008 B2
7460909 Koh et al. Dec 2008 B1
7539533 Tran May 2009 B2
20010005773 Larsen et al. Jun 2001 A1
20010020122 Steuer et al. Sep 2001 A1
20010039376 Steuer et al. Nov 2001 A1
20010044700 Kobayashi et al. Nov 2001 A1
20020026106 Khalil et al. Feb 2002 A1
20020035318 Mannheimer et al. Mar 2002 A1
20020038079 Steuer et al. Mar 2002 A1
20020042558 Mendelson Apr 2002 A1
20020049389 Abreu Apr 2002 A1
20020062071 Diab et al. May 2002 A1
20020111748 Kobayashi et al. Aug 2002 A1
20020117173 Lynn et al. Aug 2002 A1
20020133068 Huiku Sep 2002 A1
20020156354 Larson Oct 2002 A1
20020161287 Schmitt Oct 2002 A1
20020161290 Chance Oct 2002 A1
20020165439 Schmitt Nov 2002 A1
20020198443 Ting Dec 2002 A1
20030023140 Chance Jan 2003 A1
20030055324 Wasserman Mar 2003 A1
20030060693 Monfre et al. Mar 2003 A1
20030139687 Abreu Jul 2003 A1
20030144584 Mendelson Jul 2003 A1
20030158466 Lynn Aug 2003 A1
20030220548 Schmitt Nov 2003 A1
20030220576 Diab Nov 2003 A1
20040010188 Wasserman Jan 2004 A1
20040015091 Greenwald et al. Jan 2004 A1
20040054270 Pewzner et al. Mar 2004 A1
20040087846 Wasserman May 2004 A1
20040107065 Al-Ali Jun 2004 A1
20040111014 Hickle Jun 2004 A1
20040127779 Steuer et al. Jul 2004 A1
20040171920 Mannheimer et al. Sep 2004 A1
20040176670 Takamura et al. Sep 2004 A1
20040176671 Fine et al. Sep 2004 A1
20040230106 Schmitt et al. Nov 2004 A1
20050016536 Rapoport et al. Jan 2005 A1
20050043763 Marcovecchio et al. Feb 2005 A1
20050080323 Kato Apr 2005 A1
20050081854 Nadjafizadeh et al. Apr 2005 A1
20050101850 Parker May 2005 A1
20050113651 Wood et al. May 2005 A1
20050113656 Chance May 2005 A1
20050113709 Millet May 2005 A1
20050119586 Coyle et al. Jun 2005 A1
20050143665 Huiku et al. Jun 2005 A1
20050168722 Forstner et al. Aug 2005 A1
20050177034 Beaumont Aug 2005 A1
20050187480 Kario et al. Aug 2005 A1
20050192488 Bryenton et al. Sep 2005 A1
20050203357 Debreczeny et al. Sep 2005 A1
20050228248 Dietiker Oct 2005 A1
20050267346 Faber et al. Dec 2005 A1
20050283059 Iyer et al. Dec 2005 A1
20060009688 Lamego et al. Jan 2006 A1
20060009809 Marcovecchio et al. Jan 2006 A1
20060015021 Cheng Jan 2006 A1
20060020181 Schmitt Jan 2006 A1
20060030763 Mannheimer et al. Feb 2006 A1
20060052680 Diab Mar 2006 A1
20060058683 Chance Mar 2006 A1
20060064024 Schnall Mar 2006 A1
20060137577 Chang et al. Jun 2006 A1
20060155207 Lynn et al. Jul 2006 A1
20060161071 Lynn et al. Jul 2006 A1
20060167362 Neumann et al. Jul 2006 A1
20060173257 Nagai et al. Aug 2006 A1
20060189880 Lynn et al. Aug 2006 A1
20060195028 Hannula et al. Aug 2006 A1
20060195041 Lynn et al. Aug 2006 A1
20060217615 Huiku et al. Sep 2006 A1
20060224058 Mannheimer Oct 2006 A1
20060225737 Iobbi Oct 2006 A1
20060235324 Lynn Oct 2006 A1
20060247501 Ali Nov 2006 A1
20060258921 Addison et al. Nov 2006 A1
20060276695 Lynn et al. Dec 2006 A9
20070027375 Melker et al. Feb 2007 A1
20070066910 Inukai et al. Mar 2007 A1
20070093721 Lynn et al. Apr 2007 A1
20070119453 Lu et al. May 2007 A1
20070123785 Lu et al. May 2007 A1
20070149860 Lynn et al. Jun 2007 A1
20070203406 Anderson et al. Aug 2007 A1
20070208269 Mumford et al. Sep 2007 A1
20070213619 Linder Sep 2007 A1
20070213620 Reisfeld Sep 2007 A1
20070213621 Reisfeld et al. Sep 2007 A1
20070213622 Reisfeld Sep 2007 A1
20070213624 Reisfeld et al. Sep 2007 A1
20070238937 Chang et al. Oct 2007 A1
20070240723 Hong et al. Oct 2007 A1
20070276262 Banet et al. Nov 2007 A1
20080009689 Benaron et al. Jan 2008 A1
20080064965 Jay et al. Mar 2008 A1
20080071155 Kiani Mar 2008 A1
20080082018 Sackner et al. Apr 2008 A1
20080091088 Kiani Apr 2008 A1
20080139908 Kurth Jun 2008 A1
20080177163 Wang et al. Jul 2008 A1
20080177358 Gammons Jul 2008 A1
20080188729 Sato et al. Aug 2008 A1
20080200775 Lynn Aug 2008 A1
20080221464 Al-Ali Sep 2008 A1
20080262362 Kolluri et al. Oct 2008 A1
20080275317 Cho et al. Nov 2008 A1
20080287756 Lynn Nov 2008 A1
20080312533 Balberg et al. Dec 2008 A1
20080314385 Brunner et al. Dec 2008 A1
Foreign Referenced Citations (50)
Number Date Country
9 200 422.9 Jul 1992 DE
0615723 Mar 1993 EP
0459284 Jan 1995 EP
0651971 Oct 1995 EP
0709107 May 1996 EP
0714670 Jun 1996 EP
0722747 Jul 1996 EP
0788805 May 1998 EP
0968734 Jan 2000 EP
1004325 Jun 2000 EP
0700690 Feb 2002 EP
0759791 Aug 2002 EP
0934723 Sep 2004 EP
1172123 Oct 2004 EP
0875258 Nov 2004 EP
1488743 Dec 2004 EP
1790283 May 2007 EP
63275325 Nov 1988 JP
2005034472 Feb 2005 JP
WO 8801149 Feb 1988 WO
WO 9009146 Aug 1990 WO
WO 9014121 Nov 1990 WO
WO9111137 Aug 1991 WO
WO 9211054 Jul 1992 WO
WO 9222244 Dec 1992 WO
WO9313706 Jul 1993 WO
WO9316629 Sep 1993 WO
WO 9406499 Mar 1994 WO
WO 9423780 Oct 1994 WO
WO 9532016 Nov 1995 WO
WO9639927 Dec 1996 WO
WO 9714462 Apr 1997 WO
WO 9728838 Aug 1997 WO
WO9851212 Nov 1998 WO
WO 9924099 May 1999 WO
WO 9945989 Sep 1999 WO
WO0021438 Apr 2000 WO
WO 0067827 Nov 2000 WO
WO0117421 Mar 2001 WO
WO0140776 Jun 2001 WO
WO0176461 Oct 2001 WO
WO0176471 Oct 2001 WO
WO03039326 May 2003 WO
WO03084396 Oct 2003 WO
WO 2004047621 Jun 2004 WO
WO2004105601 Dec 2004 WO
WO 2005065757 Jul 2005 WO
WO2006092624 Sep 2006 WO
WO2007051066 May 2007 WO
WO2008097411 Aug 2008 WO
Related Publications (1)
Number Date Country
20090210163 A1 Aug 2009 US
Provisional Applications (1)
Number Date Country
61066181 Feb 2008 US